Impax Laboratories, Inc. (NASDAQ:IPXL) Given a $21.00 Price Target by Deutsche Bank AG Analysts

Deutsche Bank AG set a $21.00 target price on Impax Laboratories, Inc. (NASDAQ:IPXL) in a report released on Monday, July 17th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Guggenheim reissued a buy rating and set a $20.00 target price on shares of Impax Laboratories in a report on Monday, March 27th. Zacks Investment Research raised shares of Impax Laboratories from a hold rating to a buy rating and set a $19.00 price objective for the company in a report on Tuesday, July 11th. BidaskClub raised shares of Impax Laboratories from a hold rating to a buy rating in a report on Wednesday, July 12th. BMO Capital Markets reaffirmed a hold rating and issued a $16.00 price objective on shares of Impax Laboratories in a report on Friday, June 23rd. Finally, Royal Bank Of Canada set a $10.00 price objective on shares of Impax Laboratories and gave the company a hold rating in a report on Saturday, April 8th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $18.56.

Shares of Impax Laboratories (NASDAQ IPXL) opened at 18.30 on Monday. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $27.29. The stock has a 50 day moving average price of $17.34 and a 200 day moving average price of $14.34. The stock’s market capitalization is $1.31 billion.

Impax Laboratories (NASDAQ:IPXL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The firm had revenue of $202.08 million during the quarter, compared to analysts’ expectations of $195.62 million. During the same quarter last year, the company posted $0.21 earnings per share. The firm’s revenue was up 17.1% compared to the same quarter last year. Equities research analysts anticipate that Impax Laboratories will post $0.68 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Impax Laboratories, Inc. (NASDAQ:IPXL) Given a $21.00 Price Target by Deutsche Bank AG Analysts” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/12/impax-laboratories-inc-nasdaqipxl-pt-raised-to-21-00-at-deutsche-bank-ag-updated-updated-updated.html.

Several hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue raised its stake in shares of Impax Laboratories by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company’s stock valued at $102,000 after buying an additional 150 shares during the period. Commerce Bank raised its position in Impax Laboratories by 12.9% in the first quarter. Commerce Bank now owns 11,460 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 1,310 shares during the last quarter. Appleton Partners Inc. MA acquired a new position in Impax Laboratories during the second quarter worth $191,000. Virtu KCG Holdings LLC acquired a new position in Impax Laboratories during the second quarter worth $231,000. Finally, Massachusetts Financial Services Co. MA raised its position in Impax Laboratories by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 83.48% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

What are top analysts saying about Impax Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Impax Laboratories Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit